e-learning
resources
Virtual 2021
07.09.2021
The ongoing threat of drug-resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effects of bedaquiline and fluoroquinolone-based treatment regimens in patients with MDR/XDR-TB on QT prolongation
E. Zhukova (Novosibirsk, Russian Federation), Y. Batyrshina (Novosibirsk, Russian Federation)
Source:
Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Session:
The ongoing threat of drug-resistant tuberculosis
Session type:
E-poster
Number:
3337
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Zhukova (Novosibirsk, Russian Federation), Y. Batyrshina (Novosibirsk, Russian Federation). The effects of bedaquiline and fluoroquinolone-based treatment regimens in patients with MDR/XDR-TB on QT prolongation. 3337
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase
Source: International Congress 2017 – Paediatric TB: MDRTB (II)
Year: 2017
Early dosing schedules of pyrazinamide-containing anti-TB treatment have no significant impact on drug-induced hepatitis
Source: ISSN=ISSN 1810-6838, ISBN=, page=69
Year: 2007
Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB
Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases
Year: 2021
Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients
Source: Eur Respir J 2005; 26: Suppl. 49, 650s
Year: 2005
Sex differences and factors influencing the duration of the QT interval in patients on anti-tuberculosis therapy
Source: Eur Respir J, 51 (2) 1702368; 10.1183/13993003.02368-2017
Year: 2018
Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB
Source: Eur Respir J 2013; 41: 1386-1392
Year: 2013
Use of shortened chemotherapy regimens in treatment of adolescents with MDR/XDR TB
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
The efficacy, safety and tolerability of the short 12-month MDR-TB regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase
Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now?
Year: 2017
Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline
Source: International Congress 2019 – Tuberculosis: a public health approach
Year: 2019
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB
Source: Eur Respir J 2016; 47: 1235-1243
Year: 2016
Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB
Source: Eur Respir J 2016; 47:1758-1766
Year: 2016
A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment
Source: Eur Respir J 2015; 45: 554-557
Year: 2015
The efficacy of treatment of patients with drug resistant tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 661s
Year: 2007
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004
Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen
Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2011
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen
Source: Eur Respir J 2002; 20: Suppl. 38, 359s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept